SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 333.18 |
| Enterprise Value ($M) | 273.53 |
| Book Value ($M) | 242.66 |
| Book Value / Share | 3.44 |
| Price / Book | 1.37 |
| NCAV ($M) | 139.82 |
| NCAV / Share | 1.98 |
| Price / NCAV | 2.38 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.34 |
| Return on Assets (ROA) | -0.32 |
| Return on Equity (ROE) | -0.49 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.31 |
| Current Ratio | 6.31 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 273.23 |
| Assets | 376.06 |
| Liabilities | 133.40 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Lynx1 Capital Management LP | 9.90 | 119.52 | |
| 13G/A | Soleus Capital Master Fund, L.P. | 9.40 | 158.37 | |
| 13G | Orbimed Advisors Llc | 4.20 | ||
| 13G/A | Commodore Capital Lp | 4.80 | -10.25 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 0.60 | -84.68 | |
| 13G/A | Point72 Asset Management, L.P. | 1.90 | -50.92 | |
| 13G | BlackRock, Inc. | 7.10 | 0.00 | |
| 13G/A | State Street Corp | 4.35 | -58.13 | |
| 13G/A | Wasatch Advisors Inc | |||
| 13G/A | Rtw Investments, Lp | 0.00 | -100.00 | |
| 13G | Betta Investment (Hong Kong) Ltd. | 8.10 | ||
| 13G | Ra Capital Management, L.p. | 9.90 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 329,109 | 1,384,080 | 23.78 | |
| 156,092 | 829,225 | 18.82 | |
| 163,687 | 1,001,093 | 16.35 | |
| 138,560 | 646,193 | 21.44 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BOLT – Bolt Biotherapeutics, Inc. | BPMC – Blueprint Medicines Corporation |
| CABA – Cabaletta Bio, Inc. | CGC – Canopy Growth Corporation |
| CGEM – Cullinan Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io